Korsana Biosciences closed a $175 million financing to advance a preclinical Alzheimer’s program based on a platform that ferries antibodies across the blood–brain barrier. The company says its approach improves brain penetration for antibody therapeutics, a crowded strategy also pursued by Roche and AbbVie in clinical stages. Korsana’s raise supplies capital to move lead candidates toward IND-enabling studies and positions the startup to compete in the brain-delivery niche, where developers aim to increase central nervous system exposure without escalating peripheral toxicity. Investors are backing platform plays that promise to broaden antibody utility in neurodegenerative disease.